Stacey R Dillon

Summary

Affiliation: ZymoGenetics Inc
Country: USA

Publications

  1. ncbi An APRIL to remember: novel TNF ligands as therapeutic targets
    Stacey R Dillon
    Department of Autoimmunity and Inflammation, ZymoGenetics, Inc 1201 Eastlake Avenue East, Seattle, Washington 98102, USA
    Nat Rev Drug Discov 5:235-46. 2006
  2. ncbi B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
    Stacey R Dillon
    Preclinical Research and Development, ZymoGenetics, Inc, 1201 Eastlake Ave East, Seattle, WA 98102, USA
    Arthritis Res Ther 12:R48. 2010
  3. ncbi IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M
    Janine Bilsborough
    Department of Immunology, ZymoGenetics Inc, Seattle, WA 98102, USA
    J Immunol 185:6023-30. 2010
  4. ncbi Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies
    Mark F Maurer
    Department of Preclinical Research and Development, ZymoGenetics, Inc, Seattle, WA, USA
    MAbs 4:69-83. 2012
  5. ncbi Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
    Stacey R Dillon
    Department of Immunology, ZymoGenetics, 1201 Eastlake Avenue East, Seattle, Washington 98102, USA
    Nat Immunol 5:752-60. 2004
  6. ncbi Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation
    Jinoh Kim
    Division of Rheumatology, University of Washington, Seattle, WA 98195, USA
    Autoimmunity 44:69-81. 2011
  7. ncbi B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Blood 107:2882-8. 2006
  8. ncbi Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006

Collaborators

Detail Information

Publications8

  1. ncbi An APRIL to remember: novel TNF ligands as therapeutic targets
    Stacey R Dillon
    Department of Autoimmunity and Inflammation, ZymoGenetics, Inc 1201 Eastlake Avenue East, Seattle, Washington 98102, USA
    Nat Rev Drug Discov 5:235-46. 2006
    ..Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together...
  2. ncbi B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
    Stacey R Dillon
    Preclinical Research and Development, ZymoGenetics, Inc, 1201 Eastlake Ave East, Seattle, WA 98102, USA
    Arthritis Res Ther 12:R48. 2010
    ..They are overexpressed in a variety of autoimmune diseases and reportedly exist in vivo not only as homotrimers, but also as BLyS/APRIL heterotrimers...
  3. ncbi IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M
    Janine Bilsborough
    Department of Immunology, ZymoGenetics Inc, Seattle, WA 98102, USA
    J Immunol 185:6023-30. 2010
    ....
  4. ncbi Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies
    Mark F Maurer
    Department of Preclinical Research and Development, ZymoGenetics, Inc, Seattle, WA, USA
    MAbs 4:69-83. 2012
    ..Characterization of this panel of IL-21 antibodies provided the basis for the selection of a therapeutic candidate antibody capable of inhibiting IL-21 activity for the treatment of autoimmune and inflammatory diseases...
  5. ncbi Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
    Stacey R Dillon
    Department of Immunology, ZymoGenetics, 1201 Eastlake Avenue East, Seattle, Washington 98102, USA
    Nat Immunol 5:752-60. 2004
    ..These data indicate that IL-31 may be involved in promoting the dermatitis and epithelial responses that characterize allergic and non-allergic diseases...
  6. ncbi Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation
    Jinoh Kim
    Division of Rheumatology, University of Washington, Seattle, WA 98195, USA
    Autoimmunity 44:69-81. 2011
    ..Signaling through BCMA enhances B cell activation following exposure to TLR9 agonists, and increased expression in SLE may contribute to the production of IgG autoantibodies...
  7. ncbi B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Blood 107:2882-8. 2006
    ..Furthermore, BLyS was found to increase the viability and proliferation of malignant B cells from WM patients. Due to the role of BLyS in WM, strategies to inhibit BLyS may potentially have therapeutic efficacy in these patients...
  8. ncbi Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
    ..6-fold increase in activity (P = .004). CONCLUSION: Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter...